Observation of Residual Cancer With Liquid Biopsy Evaluation (ORACLE)
Enrolling By Invitation
18-99 years
All
Phase
N/A
200 participants needed
1 Location
Brief description of study
The purpose of ORACLE is to demonstrate the ability of a novel ctDNA assay developed by Guardant Health to detect recurrence in individuals treated for early-stage solid tumors. It is necessary that ctDNA test results are linked to clinical outcomes in order to demonstrate clinical validity for recurrence detection and explore its value in a healthcare environment subject to cost containment.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: solid tumors
-
Age: Between 18 Years - 99 Years
-
Gender: All
Male and Female, Age 18 or older, with invasive bladder, ureteral, or renal pelvis carcinoma, NSCLC, or breast cancer
Updated on
01 Aug 2024.
Study ID: 850191
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com
